ipilimumab,nivolumab,cabozantinib
exelixis,bms
['lba8', 'nivo', 'cabozantinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic-313', 'ipilimumab', 'nivolumab', 'renal,(-adrenal)']
presidential symposium iii
#esmo22 lba8 - phase iii study of #cabozantinib (c) in combination with #nivolumab (n) and #ipilimumab (i) in previously untreated advanced #renal cell #carcinoma (arcc) of imdc intermediate or poor risk (cosmic-313) 
Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte
Views Mine